MaaT Pharma Announces Resignation of an Independent Board Member Lyon, France, May 10th, 2022 –…
MaaT PharmaMay 10, 2022
MaaT Pharma Reports Cash and Revenues for first quarter 2022 As of March 31, 2022,…
MaaT PharmaMay 5, 2022
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry…
MaaT PharmaApril 21, 2022
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview As of December…
MaaT PharmaApril 14, 2022
MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in…
MaaT PharmaApril 7, 2022
Monthly information regarding the total number of voting rights and shares comprising the share capital…
MaaT PharmaApril 4, 2022
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients…
MaaT PharmaMarch 28, 2022
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux Lyon, France, March…
MaaT PharmaMarch 21, 2022
